A Prospective Study Comparing Leukocyte-Poor Platelet-Rich Plasma Combined with Hyaluronic Acid and Autologous Microfragmented Adipose Tissue in Patients with Early Knee Osteoarthritis.
29 Jun 2021-Stem Cells and Development (Mary Ann Liebert, Inc., publishers 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA)-Vol. 30, Iss: 13, pp 651-659
TL;DR: The authors compared the clinical efficacy of repeated doses of leucocyte-poor platelet-rich plasma (LP-PRP) plus hyaluronic acid (HA) to a single dose of autologous microfragments.
Abstract: The objective of this study was to compare the clinical efficacy of repeated doses of leucocyte-poor platelet-rich plasma (LP-PRP) plus hyaluronic acid (HA) to a single dose of autologous microfrag...
Citations
More filters
TL;DR: The most commonly used preparations are hyaluronic acid (HA), glucocorticosteroids (GS), and platelet-rich plasma (PRP) in recent years as discussed by the authors .
Abstract: Osteoarthritis (OA) can be defined as the result of pathological processes of various etiologies leading to damage to the articular structures. Although the mechanism of degenerative changes has become better understood due to the plethora of biochemical and genetic studies, the drug that could stop the degenerative cascade is still unknown. All available forms of OA therapy are based on symptomatic treatment. According to actual guidelines, comprehensive treatment of OA should always include a combination of various therapeutic options aimed at common goals, which are pain relief in the first place, and then the improvement of function. Local treatment has become more common practice, which takes place between rehabilitation and pharmacological treatment in the hierarchy of procedures. Only in the case of no improvement and the presence of advanced lesions visible in imaging tests, should surgery be considered. Currently, an increasing number of studies are being published suggesting that intra-articular injections may be as effective or even more effective than non-steroidal anti-inflammatory drugs (NSAIDs) and result in fewer systemic adverse events. The most commonly used preparations are hyaluronic acid (HA), glucocorticosteroids (GS), and also platelet-rich plasma (PRP) in recent years. This review aims to present the mechanism of action and clinical effectiveness of different pharmacological options in relieving pain and improving functions in OA as well as the emerging approach in intra-articular treatment with PRP.
13 citations
01 Sep 2021
TL;DR: This manuscript represents an updated understanding of adipose tissue, including its anatomy, functions in the human body, and role as a perivascular cellular source for tissue renewal, in addition to its role in providing cushioning and support to various structures.
Abstract: Introduction Over the past decade, human adipose-derived mesenchymal stem/signaling/stromal cell (ADSC) therapies have become increasingly popular as a biologic treatment for a variety of orthopedic conditions. ADSCs represent a source of stromal cells with biologic properties that allow for paracrine and immunomodulatory functions and the ability to differentiate into various downstream cellular tissues. Before considering the use of adipose tissue as a cellular source, it is imperative to understand its anatomy and physiology and its roles in the human body. Objectives To review the current literature regarding the anatomy, physiology, and various roles of human adipose tissue, as well as harvesting techniques and its role in biologic therapy. Methods A comprehensive literature review that included searches of PubMed, medline, EMBASE, and Google Scholar database(s), including both preclinical and clinical studies, was performed. Results This manuscript represents an updated understanding of adipose tissue, including its anatomy, functions in the human body, and role as a perivascular cellular source for tissue renewal, in addition to its role in providing cushioning and support to various structures. Conclusion Adipose tissue is widespread throughout the body and serves multiple physiologic functions. It can be harvested through several techniques and is an abundant source of bioactive molecules and ADSCs. Research in orthopedic surgery has begun using adipose tissue as a source of homologous and non-homologous cell and tissue applications. Future study will continue to investigate optimal sources of adipose-derived cells and tissues, and its therapeutic applications in orthopedics.
11 citations
TL;DR: A systematic review of biologic therapies for knee OA is presented in this article , where the authors assess the following: (1) study methodologies; (2) cell preparations and formulations; (3) patient-reported outcome scores; and (4) structural changes.
Abstract: Use of "orthobiologics" continues to expand for patients who have knee osteoarthritis (OA). We sought to perform a systemic review of biologic therapies relative to comparative groups, including the following: (1) platelet-rich plasma (PRP); (2) bone marrow-derived mesenchymal stem cells (BMSCs); (3) adipose-derived mesenchymal stem cells (ADSCs); and (4) amniotic-derived mesenchymal stem cells (AMSCs). We assessed the following: (1) study methodologies; (2) cell preparations and formulations; (3) patient-reported outcome scores (PROMs); and (4) structural changes.PubMed, Cochrane Library, and Embase databases were queried (2013-2021) to conduct a systematic review of biologic therapies for knee OA, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eighty-two studies were included: PRP (51); BMSC (15); ADSC (11); and AMSC (5). Study evaluations were made using the Modified Coleman Methodology Score. PROMs included the Western Ontario and McMaster Universities Arthritis Index and the Visual Analog Scale. Structural change evaluations included ultrasounds, radiographs, or magnetic resonance imaging.PRP comprised a majority of the studies (n = 51), most with "fair" to "good" Modified Coleman Methodology Score. Studies had variable cell preparations and formulations, with comparison study results leading to inconsistent PROMs, and structural changes. A limited number of studies were included for BMSC, ADSC, and AMSC, all with similar findings to PRP.Available literature evaluating "orthobiologics" for knee OA remain nonsuperior to comparison cohorts. Higher level studies with larger sample sizes and improved methodologies are warranted to suggest differences. Despite a growth of "orthobiologics" in clinics, this updated systematic review highlights the uncertain efficacy for use in knee OA.
8 citations
TL;DR: Clinicians should interpret the results of the 19 assessed meta-analyses of clinical studies on the management of primary knee osteoarthritis with stem cells with caution and should be cautious of the conclusions drawn therein.
Abstract: (1) Background: Conclusions of meta-analyses of clinical studies may substantially influence opinions of prospective patients and stakeholders in healthcare. Nineteen meta-analyses of clinical studies on the management of primary knee osteoarthritis (pkOA) with stem cells, published between January 2020 and July 2021, came to inconsistent conclusions regarding the efficacy of this treatment modality. It is possible that a separate meta-analysis based on an independent, systematic assessment of clinical studies on the management of pkOA with stem cells may reach a different conclusion. (2) Methods: PubMed, Web of Science, and the Cochrane Library were systematically searched for clinical studies and meta-analyses of clinical studies on the management of pkOA with stem cells. All clinical studies and meta-analyses identified were evaluated in detail, as were all sub-analyses included in the meta-analyses. (3) Results: The inconsistent conclusions regarding the efficacy of treating pkOA with stem cells in the 19 assessed meta-analyses were most probably based on substantial differences in literature search strategies among different authors, misconceptions about meta-analyses themselves, and misconceptions about the comparability of different types of stem cells with regard to their safety and regenerative potential. An independent, systematic review of the literature yielded a total of 183 studies, of which 33 were randomized clinical trials, including a total of 6860 patients with pkOA. However, it was not possible to perform a scientifically sound meta-analysis. (4) Conclusions: Clinicians should interpret the results of the 19 assessed meta-analyses of clinical studies on the management of pkOA with stem cells with caution and should be cautious of the conclusions drawn therein. Clinicians and researchers should strive to participate in FDA and/or EMA reviewed and approved clinical trials to provide clinically and statistically valid efficacy.
5 citations
TL;DR: In this article , the authors provided a synopsis of key research themes and individual studies from the clinical osteoarthritis (OA) field, focused on epidemiology and therapy, including the importance of several comorbidities in predicting OA incidence and prevalence, surgical approaches that can reduce the risk of post-traumatic OA, the heterogenous but nevertheless relatively stable nature of OA subgroup trajectories, the paucity of robust studies particularly of surgery for OA and the very modest benefit of many therapies under evaluation in trials.
4 citations
References
More filters
TL;DR: Prevalence and severity of health loss were weakly correlated and age-specific prevalence of YLDs increased with age in all regions and has decreased slightly from 1990 to 2010, but population growth and ageing have increased YLD numbers and crude rates over the past two decades.
7,021 citations
TL;DR: This classification of the different platelet concentrates into four categories, depending on their leucocyte and fibrin content, should help to elucidate successes and failures that have occurred so far, as well as providing an objective approach for the further development of these techniques.
1,454 citations
Tufts Medical Center1, University of Southampton2, University of Oxford3, University of Melbourne4, Erasmus University Rotterdam5, Duke University6, Lund University7, University of Otago8, McMaster University9, University of A Coruña10, National Autonomous University of Mexico11, Peking University12, Hospital for Special Surgery13, University of Tampere14, Health Science University15, University of Delaware16, Drexel University17, Coventry Health Care18, University of Warwick19
TL;DR: These guidelines offer comprehensive and patient-centered treatment profiles for individuals with Knee, Hip, and Polyarticular OA that are derived from expert consensus and based on objective review of high-quality meta-analytic data.
1,453 citations
TL;DR: Evidence that leads to the proposal that during local injury, MSCs are released from their perivascular location, become activated, and establish a regenerative microenvironment by secreting bioactive molecules and regulating the local immune response is discussed.
1,402 citations
TL;DR: Allogeneic MSC treatments, categorized as a drug by regulatory agencies, have been widely pursued, but new studies demonstrate the efficacy of autologous MSC therapies, even for individuals affected by a disease state.
Abstract: Mesenchymal stem cells (MSCs) are partially defined by their ability to differentiate into tissues including bone, cartilage and adipose in vitro, but it is their trophic, paracrine and immunomodulatory functions that may have the greatest therapeutic impact in vivo. Unlike pharmaceutical treatments that deliver a single agent at a specific dose, MSCs are site regulated and secrete bioactive factors and signals at variable concentrations in response to local microenvironmental cues. Significant progress has been made in understanding the biochemical and metabolic mechanisms and feedback associated with MSC response. The anti-inflammatory and immunomodulatory capacity of MSC may be paramount in the restoration of localized or systemic conditions for normal healing and tissue regeneration. Allogeneic MSC treatments, categorized as a drug by regulatory agencies, have been widely pursued, but new studies demonstrate the efficacy of autologous MSC therapies, even for individuals affected by a disease state. Safety and regulatory concerns surrounding allogeneic cell preparations make autologous and minimally manipulated cell therapies an attractive option for many regenerative, anti-inflammatory and autoimmune applications.
990 citations